stockrowAmylyx Pharmaceuticals, Inc.
AMLX Healthcare Drug Manufacturers Specialty & Generic
Amylyx Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $87.4 million, down 77.1% from fiscal 2023.
- Revenue
- −100.6%
- EPS
- +15.2%
- Free cash flow
- −24.5%
Quarter to June 2026, against a year earlier
Follow AMLX
Alert me
Amylyx Pharmaceuticals, Inc. (AMLX) P/B ratio
As of 5 November 2026, Amylyx Pharmaceuticals, Inc. (AMLX) trades at a P/B ratio of 12.9×. Over the past ten years it has ranged from 0.0× (March 2022) to 18.4× (August 2026); the current reading is higher than 91% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 1.8× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2024 | 1.6× | (32.68%) |
| FY2023 | 2.3× | (62.42%) |
| FY2022 | 6.2× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Dec 2024 | 1.6× | 39.03% |
| Sep 2024 | 1.1× | 129.75% |
| Jun 2024 | 0.5× | (13.66%) |
| Mar 2024 | 0.6× | (75.59%) |
| 7 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| RGC Regencell Bioscience Holdings Limited compare | n/m |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | n/m |
| SUPN Indivior Pharmaceuticals Inc. compare | n/m |
| PRGO Perrigo Company plc compare | 0.9× |
| PBH Prestige Consumer Healthcare Inc. compare | 1.1× |
| TRLV Trulieve Cannabis Corp. compare | 2.8× |
| AMLX Amylyx Pharmaceuticals, Inc. | 12.9× |
| HIMS Hims & Hers Health, Inc. compare | 17.2× |
| LQDA Liquidia Corporation compare | 20.4× |
| Drug Manufacturers Specialty & Generic industry median | 1.8× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on AMLX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement